Search

Your search keyword '"Forster, Martin D"' showing total 165 results

Search Constraints

Start Over You searched for: Author "Forster, Martin D" Remove constraint Author: "Forster, Martin D"
165 results on '"Forster, Martin D"'

Search Results

1. Author Correction: The evolution of lung cancer and impact of subclonal selection in TRACERx

3. Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation

4. The evolution of non-small cell lung cancer metastases in TRACERx

5. The evolution of lung cancer and impact of subclonal selection in TRACERx

6. Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists

7. A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors

8. Multi-institutional, International Evaluation of Practice Patterns and Outcomes for Recurrent and Metastatic Sinonasal Undifferentiated Carcinoma

9. Efficacy and safety of dendrimer-enhanced (DEP) cabazitaxel (CTX-SPL9111) in advanced esophagogastric cancers in a phase 1/2 trial.

10. Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC

11. CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer

12. Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours

13. Somatostatin receptor 2 expression in nasopharyngeal cancer is induced by Epstein Barr virus infection: impact on prognosis, imaging and therapy

14. Effect of statin treatment on the risk of cancer in patients with heart failure: A target trial emulation study.

15. Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation

16. Personalising monitoring for chemotherapy patients through predicting deterioration in renal and hepatic function

18. A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer

20. Body composition and lung cancer-associated cachexia in TRACERx

21. The evolution of lung cancer and impact of subclonal selection in TRACERx

22. Evolutionary characterization of lung adenocarcinoma morphology in TRACERx

23. Supplementary Data from Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

24. Data from Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

26. Supplementary Methods from BGC 945, a Novel Tumor-Selective Thymidylate Synthase Inhibitor Targeted to α-Folate Receptor–Overexpressing Tumors

27. Supplementary Table 3 from BGC 945, a Novel Tumor-Selective Thymidylate Synthase Inhibitor Targeted to α-Folate Receptor–Overexpressing Tumors

29. Biphenotypic sinonasal sarcoma: European multicentre case-series and systematic literature review

30. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution

32. International Multicenter Study of Clinical Outcomes of Sinonasal Melanoma Shows Survival Benefit for Patients Treated with Immune Checkpoint Inhibitors and Potential Improvements to the Current TNM Staging System

33. Clinical development of new drug-radiotherapy combinations

34. Multicenter Analysis of Clinical Outcomes of Sinonasal Mucosal Melanoma

35. Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma

38. Predicting Progression Free Survival after Systemic Therapy in Advanced Head and Neck Cancer: Bayesian regression and Model development

39. A Phase I study of the safety, pharmacokinetics and efficacy of navitoclax plus docetaxel in patients with advanced solid tumors

40. Corrigendum: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution

44. Estimated impact of the COVID-19 pandemic on cancer services and excess 1-year mortality in people with cancer and multimorbidity: near real-time data on cancer care, cancer deaths and a population-based cohort study

46. Abstract CT054: The development of a personalized autologous clonal neoantigen T cell therapy for the treatment of solid cancer using the VELOSTM manufacturing platform generates highly potent and reactive CD8+ and CD4+ T cells for clinical use

48. Estimating excess mortality in people with cancer and multimorbidity in the COVID-19 emergency

49. Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study

50. Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

Catalog

Books, media, physical & digital resources